The new non-executive employee received an option to purchase 35,000 shares of Annexon common stock. The option carries a ten-year term and an exercise price per share equal to $2.60, which was the ...
OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its partnership with the ...
“This new loan financing strengthens our financial position, providing additional support for developing Mother Bracelet,” said Koji Eguchi, Chief Executive Officer of MEDIROM.
Signature d’un avenant n°4 au contrat de financement obligataire en vigueur afin de poursuivre le retournement stratégique de Safe ...
Brian Stephenson, Ph.D. will depart from the Company for personal reasons. Dr. Stephenson's departure was not the result of a disagreement with the Company on any matters relating to the Company’s ...
AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific
Under the terms of the new Contract Manufacturing Agreement, effective as of March 17, 2025, AVITA Medical is to manufacture PermeaDerm at its state-of-the-art manufacturing facility in Ventura, ...
Hyperfine, Inc. sold nine commercial Swoop® systems in the fourth quarter of 2024, compared to seven in the fourth quarter of 2023. Gross margin for the fourth quarter of 2024 was $0.8 million, ...
FARMINGDALE, N.Y., March 17, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal second quarter ended January 31, 2025, ...
F573 is a caspase inhibitor and a potential Category 1 new drug for the treatment of acute/acute on-chronic liver failure (“ALF/ACLF”). Completion of the Phase 2 clinical trial of F573 as a treatment ...
Cash receipts totaled $4.0 million in the fourth quarter and $46.3 million for the full year 2024 EMERYVILLE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the ...
EMERYVILLE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its ...
Net loss from continuing operations for the fourth quarter of 2024 was $8.7 million, or $0.08 net loss per basic and diluted share, compared to a net loss of $62.5 million, or $0.63 net loss per basic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback